UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 24, 2022

LAREDO PETROLEUM, INC.

(Exact name of registrant as specified in charter)

Registrant’s telephone number, including area code: (918) 513-4570

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company              ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

On August 24, 2022, Laredo Petroleum, Inc. (the “Company”) announced the departure of T. Karen Chandler, the Company’s Senior Vice President and Chief Operating Officer, effective immediately. Dr. Chandler’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company does not intend to fill the Chief Operating Officer role, and Dr. Chandler’s responsibilities will be absorbed by other members of the Company’s management team.

Dr. Chandler will receive certain payments and benefits pursuant to the Company’s Executive Severance Plan, as disclosed in the Company’s most recent definitive proxy statement on Schedule 14A, as filed with the Securities and Exchange Commission on April 7, 2022. She will receive such payments and benefits provided she signs and subsequently does not revoke a Confidentiality, Non-Disparagement and Non-Solicitation Agreement, including her release of claims in favor of the Company, and she complies with the provisions of the Severance Plan, including the customary non-disclosure covenants.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.